FIG. 2.

Quinolone pharmacodynamics with S. aureus. (A) Ciprofloxacin and susceptible S. aureus. The MIC₉₀ and the MPC₉₀ were obtained from the data in Table 2; pharmacokinetic data were determined for 400-mg doses of ciprofloxacin administered intravenously three times per day (13). (B) Garenoxacin and susceptible S. aureus. The MIC₉₀ and the MPC₉₀ were obtained from the data in Table 2; pharmacokinetic data were determined for 400-mg doses of garenoxacin administered orally once daily (7). (C) Garenoxacin and ciprofloxacin-resistant S. aureus. The MIC₉₀ and the MPC₉₀ were obtained from the data in Table 2; pharmacokinetic data were determined for 600-mg doses of garenoxacin administered orally once daily (P. Hale, personal communication).